Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Placebo in Resected High-Risk Stage II Melanoma
NCT03553836Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2018
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Pembrolizumab with Placebo (2 arms). Primary endpoint: Recurrence-free Survival. Started Sep 2018; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03553836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553836.